Skip to content

Study · Animal study (in vivo) · mouse · 2015

6 results

Exendin-4 Loaded Nanoparticles with a Lipid Shell and Aqueous Core Containing Micelles for Enhanced Intestinal Absorption.

Chen C, Zhu X, Dou Y, Xu J, Zhang J, Fan T, Du J, Liu K, Deng Y, Zhao L, Huang Y

Journal of biomedical nanotechnology1 May 2015Cited by 22 (Europe PMC)

PMID26349398 (opens in a new tab)DOI10.1166/jbn.2015.1971 (opens in a new tab)PepBankPUB-26349398
Publisher pagePubMedAsk about this study
Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

5 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In diabetic KKAy mice, intestinal exendin‑4-loaded nanoparticles produced a marked glucose-lowering effect.

    In plain wordsIn mice with diabetes, intestinal exendin‑4 nanoparticles lowered blood sugar.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseBlood glucose
    Study

    mousen: not reported in source

    Diabetic KKAy mice
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · intestinalAs given in this study (mouse).

    Source sentences

    Summary
    Pharmacodynamic studies in diabetic KKAy mice demonstrated that the exendin-4-loaded nanoparticles exhibited a marked hypoglycemia effect with a pharmacological availability of 12.7% after intestinal administration.
  2. 02AnimalAnimal study (in vivo)Pharmacokinetics

    In diabetic KKAy mice, exendin‑4 nanoparticles had pharmacological availability of 12.7% after intestinal administration.

    In plain wordsIn mice with diabetes, intestinal exendin‑4 nanoparticles had 12.7% pharmacological availability.

    Peptide
    Exenatide (exendin-4)
    Outcome
    Not applicablePharmacological availability
    Study

    mousen: not reported in source

    Diabetic KKAy mice
    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    Dose not stated · intestinalAs given in this study (mouse).

    Measurements

    Pharmacological availability
    12.7%
    intestinal nanoparticles

    Source sentences

    Summary
    Pharmacodynamic studies in diabetic KKAy mice demonstrated that the exendin-4-loaded nanoparticles exhibited a marked hypoglycemia effect with a pharmacological availability of 12.7% after intestinal administration.
  3. 03AnimalOther designPharmacokinetics

    In situ, exendin‑4 crossed the epithelium into intestinal capillaries while lipid materials largely remained in the epithelium.

    In plain wordsIn situ tests showed exendin‑4 transport into intestinal capillaries while most lipid material remained in the intestinal lining.

    Peptide
    Exenatide (exendin-4)
    Outcome
    Not applicableIntestinal epithelial transport
    Study

    n: not reported in source

    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The in situ study showed that exendin-4 could be transported across the epithelium into intestinal capillaries, while the lipid materials largely remained in the epithelium.
  4. 04LabIn vitro (cells)Pharmacokinetics

    In vitro, nanoparticles enhanced cellular uptake of encapsulated exendin‑4.

    In plain wordsIn cells, nanoparticles enhanced uptake of encapsulated exendin‑4.

    Peptide
    Exenatide (exendin-4)
    Outcome
    IncreaseCellular uptake
    Study

    n: not reported in source

    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The nanoparticles greatly enhanced the cellular uptake and transport of encapsulated exendin-4 in vitro.
  5. 05LabIn vitro (cells)Pharmacokinetics

    In vitro, nanoparticles enhanced transport of encapsulated exendin‑4.

    In plain wordsIn cells, nanoparticles enhanced transport of encapsulated exendin‑4.

    Peptide
    Exenatide (exendin-4)
    Outcome
    IncreaseCellular transport
    Study

    n: not reported in source

    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The nanoparticles greatly enhanced the cellular uptake and transport of encapsulated exendin-4 in vitro.

Studies that did not test the peptide alone1

In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Exenatide (exendin-4).

  1. 06LabNot a test of Exenatide (exendin-4) aloneIn vitro (cell-free)Other

    In laboratory formulation tests, exendin‑4 nanoparticle encapsulation efficiency reached 97.7%.

    In plain wordsIn lab tests, nanoparticles encapsulated exendin‑4 with 97.7% efficiency.

    Peptide
    Exenatide (exendin-4)
    Outcome
    Not applicableEncapsulation efficiency
    Study

    n: not reported in source

    Outcome group
    Formulation, delivery and stability · Pharmacology

    Measurements

    Encapsulation efficiency
    97.7%
    nanoparticles

    Source sentences

    Summary
    The drug encapsulation efficiency of the nanoparticles reached 97.7%.

    In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.